LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRXBiotechnology
-$0.39 today
- Market cap
- $1.30B
- Beta
- 0.71
- P/E (TTM)
- -21.4
- EPS (TTM)
- -$1.39
Volume 0.36M
Average 0.23M
LBRX Total Liabilities
Everything the company owes to creditors and other parties.
LB Pharmaceuticals Inc Common StockNASDAQ: LBRX
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities rises 66.9% from a year ago
Total liabilities stood at $14.79M at the end of Q1 FY2026, up 66.9% from a year earlier and up 27.2% from the prior quarter. Over 3 fiscal years it compounded at -38.6% a year.
Context
- Total liabilities amounted to 3.8% of total assets at the end of Q1 FY2026, down 42.3 pp from a year earlier.
- Total liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +66.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 11.62M USD
- Year-over-year change
- -90.9%
- 3-year CAGR
- -38.6%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.62M | -90.9% |
| FY2024 | 2024-12-31 | 128.09M | +59.9% |
| FY2023 | 2023-12-31 | 80.13M | +59.3% |
| FY2022 | 2022-12-31 | 50.3M | — |
Total Liabilities vs competitors
How LBRX compares with its peers on the latest reported figures
- LBRX's Mar 2026 total liabilities of $14.79M is the 9th highest of the 10 companies compared; the peer median is $83.2M.
- Its year-over-year change of +66.9% is the 4th highest of 10, against a peer median of +16.1%.
- Total liabilities amounts to 3.8% of total assets for LBRX, versus a peer median of 11.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $296.65B | +474318.1% | +47.0% | 312.0% | |
| Sep 2026 | $406.66M | -1.7% | +21.6% | 22.7% | |
| Jun 2026 | $322.78M | +131.9% | -32.0% | 27.9% | |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | $106.25M | -0.1% | +78.1% | 9.9% |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $83.2M | +193.1% | -53.6% | 54.1% |
| Mar 2026 | $32.89M | +0.2% | -27.8% | 11.9% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $26.09M | +60.8% | +31.9% | 5.2% |
| Mar 2026 | $18.95M | +2.1% | +4.5% | 4.5% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $14.79M | +66.9% | -38.6% | 3.8% |
| Mar 2026 | $11.89M | +16.1% | +23.3% | 4.3% | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding LBRX) | $83.2M | +16.1% | +21.6% | 11.9% | |
Competitors are the stored peer set for LBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
Intrinsic Alpha fair value
Locked
Current Price
$40.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.